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ABSTRACT
Human immunodeficiency virus (HIV) therapy
has evolved over the last 20 years from mono-
drug therapy given five times daily to regimens
consisting of three or four drugs combined in a
single-tablet dosed once daily. To allow once-
daily administration, several drugs require
pharmacokinetic boosting by a concomitantly
administered P-glycoprotein and cytochrome
P450 inhibitor such as ritonavir. The
availability of cobicistat provides an
alternative to ritonavir to those who are
intolerant to this drug, and the opportunity
for co-formulated single-tablet regimens
consisting of tenofovir/emtricitabine,
cobicistat and elvitegravir, atazanavir or
darunavir. The cobicistat/elvitegravir-based
regimen is well tolerated and patients achieved
high rates of HIV RNA suppression in clinical
trials. Cobicistat inhibits renal tubular secretion
of creatinine, resulting in increased serum
creatinine concentrations and reduced
estimated glomerular filtration rate, with a
new set point reached after 4 weeks. Treatment
limiting renal toxicity with cobicistat/
elvitegravir and tenofovir disoproxil fumarate
is infrequent and may be further reduced when
cobicistat is co-formulated with tenofovir
alafenamide fumarate, a novel formation of
tenofovir currently undergoing clinical trials.
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INTRODUCTION
Since the introduction of zidovudine in 1987,
human immunodeficiency virus (HIV) therapy
has been revolutionised with the availability of
over 30 agents across six drug classes. Current
British HIV Association (BHIVA) guidelines
recommend treatment with a nucleoside/
nucleotide reverse transcriptase inhibitor
(NRTI) backbone together with a non-
nucleoside reverse transcriptase inhibitor
(NNRTI), ritonavir-boosted protease inhibitor
(PI), or integrase inhibitor (II) as a first-line
therapy for the treatment-naı¨ve HIV-positive
individuals [1]. Whilst the majority of patients
achieve an undetectable HIV RNA level on these
treatments, high levels of adherence are
required for successful treatment outcomes;
recent clinical trials show significantly worse
outcomes amongst sub-optimally adherent
individuals (defined as adherence \95%) on
NNRTI- and PI-based first-line regimens [2, 3].
Side effects remain the commonest reason for
switching antiretroviral therapy [4, 5], and side
effects are a common reason for late and missed
doses [6]. Several agents [e.g. lamivudine,
emtricitabine (FTC), efavirenz (EFV),
nevirapine and raltegravir (RTG)] have a low
genetic barrier to resistance and may be
rendered ineffective by single nucleotide
substitutions in the viral genome [7–9], while
others [e.g. rilpivirine (RPV) and abacavir (ABC)]
may have limited potency at high HIV viral
load, are best avoided in patients with chronic
kidney disease [e.g. tenofovir (TDF), atazanavir
(ATV)], or in those at high risk of coronary heart
disease (ABC), or should not be used in HLA
B5701-positive patients (ABC) [1]. While many
patients prefer a once-daily regimen consisting
of a small number of tablets, some agents (e.g.
RTG) require twice-daily dosing. As a result,
antiretroviral therapy continuous to evolve as
agents with favourable side-effect profiles, low
pill burden, potency across viral loads, and
limited cross resistance with existing
antiretrovirals become available for use in
clinical practice. Co-formulation of such drugs
with the NRTI backbone into a single-tablet
regimen is an attractive strategy to improve
patient convenience, adherence, long-term
outcomes and, in some countries, to lower
prescription charges.
Cobicistat (COBI), a novel
pharmacoenhancer, was recently licensed for
the treatment of HIV infection when
administered as Stribild (Gilead Inc., Foster
City, CA, USA), a single-tablet regimen
containing COBI, elvitegravir (EVG), a novel
II, and an NRTI backbone of TDF/FTC. Similar
to many PI, EVG requires boosting in order to
maintain therapeutic plasma concentrations.
Co-administration of COBI maintains EVG
plasma concentrations well above the protein-
adjusted IC95 for wild-type HIV for more than
24 h, allowing once-daily administration [10].
COBI is also being developed as a
pharmacoenhancer for HIV PI, with the
potential to create fixed-dose combinations of
COBI/ATV or COBI/darunavir (DRV). Finally, a
novel formulation of tenofovir [tenofovir
alafenamide fumarate (TAF)] is currently
undergoing clinical trials which may lead to
additional COBI-based combination tablets for
HIV treatment [11]. In this review, we discuss
the concept of pharmacoenhancing, the
pharmacology of COBI, relevant clinical trial
data and its potential role in clinical practice.\
METHODS
Clinical trials, pharmacokinetic and toxicity
studies performed with COBI were reviewed
for the purpose of this article. Relevant studies
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were identified by searching the published
literature (PubMed) and conference abstracts
from January 2008 up to July 2013 for
‘‘cobicistat’’, ‘‘elvitegravir’’ and ‘‘Stribild’’. The
analysis in this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
RITONAVIR AND THE CONCEPT
OF BOOSTING
Ritonavir (RTV) is an HIV PI which has been
available since 1996. While its unfavourable
side-effect profile at doses required to inhibit
HIV replication limits its role as anti-HIV
therapy, it has potent inhibitory effects on
cytochrome P450 (CYP) and P-glycoprotein
[12]. Inhibition of the efflux transporter
P-glycoprotein results in increased drug
absorption, and inhibition of CYP (especially
3A4) in reduced elimination of concomitantly
administered medications. The
pharmacokinetic profile of RTV has resulted in
its widespread use as pharmacoenhancer of
other PI, most commonly lopinavir, ATV and
DRV. RTV prolongs the terminal elimination
half-life of the co-administered PI and increases
PI trough concentration, allowing once- or
twice-daily administration of the ‘‘boosted’’ PI.
This inhibitory effect on P-glycoprotein and
CYP3A4 is achieved at low, sub-therapeutic




Inhibition of CYP3A4 (and other CYP iso-
enzymes) will affect concurrently administered
medications metabolised by this pathway. COBI
interactions are less widely studied than RTV;
while data are awaited it may be necessary to
draw on the experience with RTV when
predicting likely COBI interactions. Some
drugs cannot be co-administered with CYP3A4
inhibitors due to significant increases in
concentrations of the co-administered agent
(e.g. fluticasone, simvastatin) while others
require dose adjustment (e.g. rifabutin, for
which interaction data with RTV and COBI is
available, and clarithromycin, for which only
the interaction with RTV has been studied—
advice for COBI is extrapolated from this). In
addition, neither RTV nor COBI is ‘clean’ in
terms of CYP inhibition; the impact of both on
hepatic enzymes is more complex than CYP3A4
inhibition alone (Table 1) [10], further
increasing the potential for important drug–
drug interactions. The low doses of ritonavir
used for boosting may still be associated with
tolerability and toxicity issues [13, 14]. There is
a paucity of data regarding the tolerability of
COBI as a single agent but when used to boost
ATV, adverse events and tolerability were
similar for COBI and RTV [15].
Table 1 Inhibitory effect of COBI and RTV on









Data are expressed as CYP iso-enzyme IC50 in
micromoles/liter. A lower value reﬂects a greater
inhibitory effect
COBI cobicistat, RTV ritonavir





Similar to RTV, COBI is a potent inhibitor of
CYP3A enzymes but has no antiviral activity
against HIV. It was specifically developed as a
pharmacoenhancer to be used alongside drugs
that are metabolised through CYP, specifically
EVG and the PI ATV and DRV. While COBI and
RTV have similar inhibitory effects on CYP3A4
and 2B6, COBI has a weaker (2D6) or no (2C8
and 2C9) inhibitory effect on other CYP
enzymes (Table 1) [10]. Additional
pharmacokinetic studies of COBI revealed
\twofold increased desipramine exposure
(reflecting limited CYP2D6 inhibition),
minimally reduced EFV exposure (suggesting
no relevant interactions with CYP2B6
substrates) and small increases in digoxin
exposure consistent with inhibition of
intestinal P-glycoprotein [16]. Similar to RTV,
cimetidine and trimethoprim, COBI is an
inhibitor of the renal multidrug and toxin
extrusion protein 1 (MATE1) [17]. As a
consequence, serum creatinine levels are
increased by approximately 10–15%, and
creatinine-based estimates of creatinine
clearance are reduced by approximately 10%
(10–15 mL/min) with COBI exposure [18, 19], a
somewhat more pronounced effect than
observed with RTV.
COBI at a dose of 150 mg once daily
increases EVG exposure to a similar degree as
RTV 100 mg (Table 2A); the EVG Ctau with COBI
was 11-fold above the protein binding-adjusted
IC95 (44.5 ng/mL) of wild-type HIV [10]. COBI/
ATV and RTV/ATV co-administration results in
similar ATV pharmacokinetic profiles (Table 2B,
C) [15, 20]. The ATV Ctau with COBI was well
above the protein binding-adjusted IC90 of wild-
type HIV (14 ng/mL) and in [90% of visits
above the Department of Health and Human
Sciences (DHHS) recommended target of
150 ng/mL [20]. COBI and RTV are also similar
in their ability to boost DRV when given once
or twice daily (Table 2D, E) [21]. The 30% lower
mean Ctau with once-daily COBI/DRV
administration is 18 times over the protein
binding-adjusted EC50 of wild-type HIV and
the recommended target for wild-type virus
(55 ng/mL). Similar DRV concentrations were
observed when COBI/DRV twice daily was co-
administered with EVG or etravirine [22]. By
contrast, tipranavir exposure was inadequately
boosted by COBI 150 mg as compared to RTV
200 mg (both given twice daily) [22].
The pharmacokinetic parameters of COBI are
similar when taken fasted or with light meals;
high-calorie, high-fat meals reduce COBI
AUCtau and Cmax by 18–24%. By contrast,
COBI-boosted EVG exposure is increased when
given with food, with AUCtau and Cmax
increased by 22–36% with light meals and by
56–91% with high-calorie, high-fat meals.
Although it is recommended that Stribild is
administered with food [23], the fasted EVG
C24h (250 ng/mL) was well over the protein-
adjusted IC95 for wild-type HIV (44.5 ng/mL)
[23], suggesting that Stribild should provide
adequate EVG exposure in the vast majority of
fasted patients. The pharmacokinetic
parameters of COBI and EVG are not affected
by co-administration of omeprazole, a proton
pump inhibitor, or famotidine, an H2-receptor
antagonist [24]. Neither COBI nor EVG requires
dose modification in patients with severe renal
impairment (creatinine clearance \30 mL/min)
[25] or moderate liver disease (Child–Pugh–
Turcotte class B) [26].
A pharmacokinetic study of 32 patients
switched from Atripla (Bristol Myers Squibb,
New York, NY, USA & Gilead Inc, Foster City,
CA, USA) (fixed-dose combination of EFV and
114 Infect Dis Ther (2013) 2:111–122
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TDF/FTC) to Stribild showed reduced EVG
concentrations during the first week as a result
of glucuronosyl transferase induction by EFV.
However, the median EFV Ctau remained above
the IC90 of wild-type HIV for at least 4 weeks
and, by the end of the first week, the median
EVG Ctau was threefold higher than the IC95,
suggesting that EFV activity is maintained while
EVG concentrations reach therapeutic
concentrations [27]. A phase IIIb study is
evaluating the safety of a regimen switch from




Due to its inhibition of CYP enzymes, it is
anticipated that COBI exposure will result in
drug–drug interactions similar to those seen
with RTV (see above). However, few studies
have examined the effects of COBI on the
plasma concentrations of other drugs and
until the results of such studies emerge, it
would appear prudent to avoid COBI in
patients who require drugs with a narrow
therapeutic index (e.g. cancer chemotherapy,
Table 2 Relative effects of cobicistat vs. ritonavir on the pharmacokinetic proﬁles of elvitegravir, atazanavir and darunavir
Mean (CV%) AUC0–24 (ng h/mL)
geometric mean
Cmax (ng/mL) Ctrough (ng/mL)
A. Pharmacokinetic proﬁle of EVG (200 mg QD) when co-administered with COBI (150 mg QD) or RTV
(100 mg QD) [10]
COBI/EVG 27,000 (29.4) 2,660 (27.6) 490 (52.9)
RTV/EVG 22,500 (32.1) 2,500 (32.1) 409 (40.5)
B. Pharmacokinetic proﬁle of ATV (300 mg QD) when co-administered with COBI (150 mg QD) or RTV
(100 mg QD) [15]
COBI/ATV 55,900 (28.2) 4,880 (24.9) 1,330 (42.7)
RTV/ATV 55,200 (27.6) 5,270 (23.6) 1,340 (40.8)
C. Week 48 pharmacokinetic proﬁle of ATV (300 mg QD) when co-administered with COBI (150 mg QD) or RTV
(100 mg QD) [20]
COBI/ATV 41,300 (33) 3,880 (36) 655
RTV/ATV 49,900 (47) 4,390 (47) 785
D. Pharmacokinetic proﬁle of DRV (800 mg QD) when co-administered with COBI (150 mg QD) or RTV
(100 mg QD) [21]
COBI/DRV 81,100 (31.0) 7,740 (21.8) 1,330 (66.8)
RTV/DRV 80,000 (34.0) 7,460 (20.3) 1,870 (83.3)
E. Pharmacokinetic proﬁle of DRV (600 mg BID) when co-administered with COBI (150 mg BID) or RTV
(100 mg BID) [22]
COBI/DRV 73,400 (19) 9,040 (19) 3,960 (30)
RTV/DRV 67,900 (22) 8,390 (21) 3,800 (27)
ATV Atazanavir, AUC area under the concentration curve, BID twice daily, C concentration, COBI cobicistat, CV
coefﬁcient of variation, DRV darunavir, EVG elvitegravir, QD once daily, RTV ritonavir
Infect Dis Ther (2013) 2:111–122 115
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digoxin) or drugs that are contraindicated or
require major dose adjustment in those on RTV.
Further and up-to-date information is available
on the HIV Drug Interactions webpage [28].
COBICISTAT-CONTAINING HIV
THERAPY: RESULTS
FROM THE PHASE III CLINICAL
TRIALS PROGRAMME
The results of three studies have been presented
to date; two studies investigated the efficacy
and safety of Stribild [29–32], while the third
study compared COBI with RTV, each co-
administered with ATV and TDF/FTC [33].
The GS-US-236-0102 and 0103 studies are
ongoing phase III, double-blind, randomised,
placebo-controlled trials of antiretroviral-naı¨ve
HIV-1-positive adults [31, 32]. Patients with
a baseline HIV RNA measurement of
[5,000 copies/mL were randomised 1:1 to
Stribild or Atripla [0102 study], or to Stribild
or TDF/FTC/ATV/RTV [0103 study]. To be
eligible, patients were required to have a
creatinine clearance (calculated by Cockcroft-
Gault) of C70 mL/min. The primary endpoint
was the proportion of patients with an
undetectable HIV RNA level (\50 copies/mL)
at 48 weeks in the intention to treat population
using the Food and Drug Administration (FDA)
snapshot analysis. In both studies, Stribild was
non-inferior to the comparator and associated
with high rates (84–87%) of HIV RNA
suppression throughout 96 weeks, low rates
(2–3%) of treatment-emergent NRTI/II
resistance, and less dizziness or abnormal
dreams (vs. EFV) and diarrhoea (vs. ATV/RTV)
(Table 3). The GS-US-216-0114 study is an
ongoing phase III, double-blind, randomised,
placebo-controlled trial of antiretroviral-naı¨ve
HIV-1-positive adults (n = 692) with baseline
HIV RNA measurements of [5,000 copies/mL
and creatinine clearance C70 mL/min who were
randomised 1:1 to COBI 150 mg or RTV 100 mg,
each given together with ATV 300 mg and TDF/
FTC once daily [33]. At 48 weeks, the COBI/ATV
regimen was non-inferior to the RTV/ATV
regimen, with 85% and 87% of patients
achieving HIV RNA \50 copies/mL,
respectively. Adverse events, including
bilirubin elevations, jaundice, nausea and
diarrhoea, and study drug discontinuations
due to adverse events occurred with equal
frequency in both arms [33]. Other ongoing
studies investigate a switch from TDF/FTC plus
an NNRTI to Stribild (ClinicalTrials.gov
identifier: NCT01495702) or TDF/FTC plus a
RTV-boosted PI to Stribild (ClinicalTrials.gov
identifier: NCT01495702), and the use of
Stribild or COBI in patients with impaired
renal function (creatinine clearance 50–89 mL/
min; ClinicalTrials.gov identifier:
NCT01363011). A small single-arm study
confirmed the safety of a switch from TDF/FTC
plus RTG to Stribild [34].
RENAL SAFETY
As described above, COBI inhibits the renal
creatinine transporter MATE1. Although
creatinine is freely filtered at the glomerulus,
some 10–15% is actively secreted in the
proximal tubule. Abrogation of tubular
creatinine secretion results in mild increases in
serum creatinine concentrations and mild
reductions in estimated creatinine clearance.
In healthy volunteers, COBI exposure resulted
in reduced creatinine clearance (as measured
with the Cockcroft-Gault formula) with
minimal change in the actual (iohexol-
measured) glomerular filtration rate (-9.9 vs.
-2.7 mL/min in those with creatinine clearance
116 Infect Dis Ther (2013) 2:111–122
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Table 3 Phase III trials of cobicistat-containing combination antiretroviral therapy regimens in treatment-naı¨ve individuals





N = 700, 89% male,






Stribild vs. Atripla (48w):
HIV RNA\50 copies/mL: 87.6%
vs. 84.1% (difference 3.6%, 95%
CI -1.6 to 8.8%)
CD4 increases: 239 vs. 209 cells/
mm3, p = 0.009
Virological failure: 14 (4%) vs. 17
(5%); 2% developed II and 2%
NRTI resistance vs. 2% NNRTI
and 1% NRTI mutations
Fasting lipids: smaller increases with
Stribild (p = 0.001)
Treatment-emergent adverse events
leading to discontinuation: 4% vs.
5%
Dizziness and abnormal dreams:
24–27% vs 7–15%
Diarrhoea and nausea were equally
common in both arms (14–23%)
Stribild non-inferior to Atripla
Trend for better viral responses on Stribild
for low (\100,000 copies/mL) and high
baseline HIV RNA
At 96 weeks, non-inferiority in terms of viral
suppression (84% vs. 82%, difference 2.7%,
95% CI -2.9 to 8.3%) was maintained,
with emergent resistance observed in 3% of





N = 708, 90% male,
median age 38, CD4
360 cells/mm3 VL 4.8
log copies/mL





HIV RNA\50 copies/mL: 89.5%
vs. 86.6% (difference 3.0%, 95%
CI -1.9 to 7.8%)
Similar CD4 increases: 207 vs.
211 cells/mm3
Virological failure: 12 (3%) vs. 8
(2%); 1% developed II and 1%
NRTI resistance vs. no NRTI/PI
resistance
Similar modest effects on fasting
cholesterol (P[ 0.2), smaller
triglycerides increase with Stribild
(P = 0.006)
Treatment-emergent adverse events
leading to discontinuation: 4% vs.
5%
Diarrhoea and nausea were equally
common in both arms (19–27%)
COBI/EVG-containing regimen non-
inferior to the PI-based regimen with a
trend towards better viral responses with
Stribild irrespective of baseline HIV RNA
At 96 weeks, rates of viral suppression were
similar (87% vs. 85%, difference 1.1%, 95%
CI -4.5 to 6.7%) with low cumulative
resistance rates (2% vs. 0%)






n = 692, median age
38, CD4 352 cells/
mm3, mean VL 4.8
log copies/mL
Randomised 1:1 to COBI
150 mg or RTV 100 mg
plus ATV 300 mg and
TDF/FTC; double-blind
COBI vs. RTV (?TDF/FTC/ATV)
(48w):
HIV RNA\50 copies/mL: 85% vs.
87% (difference 2.2%, 95% CI -
7.4 to 3.0%)
Similar CD4 increases: 219 vs. 213
cells/mm3
Virological failure: 20 (5.8%) vs. 14
(4.0%); 2 vs. 0 patients developed
M184V; no PI mutations
Similar modest effects on fasting
lipids
Treatment-emergent adverse events
leading to discontinuation 7.3% vs.
7.2%
Adverse events, including bilirubin
elevations, jaundice, nausea and
diarrhoea, occurred with equal
frequency in both arms
COBI-containing regimen non-inferior to
the RTV-containing regimen
Consistent rates of viral suppression were
observed across CD4 cell count and
baseline HIV RNA strata
ATV atazanavir, COBI cobicistat, FTC emtricitabine, II integrase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside/
nucleotide reverse transcriptase inhibitor, PI protease inhibitor, RTV ritonavir, TDF tenofovir disoproxil fumarate
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C80 mL/min, and -11.9 vs. -3.6 mL/min in
those with creatinine clearance 50–79 mL/min)
[35]. Baseline creatinine clearance (range
50–140 mL/min) did not affect the magnitude
of the reduction in creatinine clearance with
COBI exposure [35]. In the 0102 and 0103
studies, serum creatinine levels in the Stribild
arm increased by approximately 10–15% in the
first 4 weeks, and creatinine clearance declined
by 10–15 mL/min [29, 30]. However, at 4 weeks
a new ‘‘set point’’ was reached, with minimal
subsequent change up to week 96 (-2.6 vs.
-1.0 mL/min for Stribild and Atripla in the
0102 study, -1.8 vs. -4.4 mL/min for Stribild
and TDF/FTC/ATV/RTV in the 0103 study) [18,
19]. In the 0114 study, patients in the COBI arm
experienced greater reductions in creatinine
clearance (-13 vs. -9 mL/min) than in the
RTV arm [33].
Five patients (1.4%) in the 0102 study, all in
the Stribild arm, had renal events (reported as
elevated serum creatinine in two, renal failure
in two, Fanconi syndrome in one; a total of four
patients had evidence of proximal tubulopathy
that led to study drug discontinuation before
week 48) [29]. Further two patients (0.6%) in
the Stribild arm discontinued study drug
between weeks 48 and 96, because of renal
adverse events consisting of serum creatinine
elevations not accompanied by proximal
tubulopathy [31]. In the 0103 study, five
patients (Stribild arm 3, ATV/RTV arm 2)
discontinued study drug due to renal events
before week 96; none had evidence of proximal
tubulopathy [32]. In the 0114 study, 1.7% and
1.4% of patients discontinued study medication
for renal events in the COBI and RTV arms, and
5 vs. 2 cases had proximal tubulopathy [33].
The low rate of renal discontinuations and
renal tubular disease suggests an overall
favourable renal safety profile of Stribild and
COBI. Indeed, data from patients with creatinine
clearance 50–89 mL/min who initiated Stribild
or substituted RTV with COBI observed no
increased rate of renal toxicity or renal
discontinuations [36]. The increases in serum
creatinine concentration and the reductions in
estimates of creatinine clearance and glomerular
filtration rate are unlikely to be of clinical
importance. Some of the renal discontinuations
were likely to be due to patients meeting pre-
specified criteria for discontinuation rather than
secondary to overt renal toxicity. Nonetheless,
the population included in the clinical trials was
at low risk of kidney injury and despite this a
small number developed significant renal
tubular disease requiring drug discontinuation.
The risk factors for TDF-induced Fanconi
syndrome and renal tubular disease remain
poorly defined but may point to an interaction
between COBI and tenofovir at renal tubular
level, as previously suggested for RTV [37].
Although such an interaction is not predicted
by in vitro studies (Fig. 1), clinicians will need to
remain alert to the nephrotoxic potential of
Stribild in clinical practice.
DISCUSSION
Cobicistat provides an alternative to ritonavir as
a pharmacoenhancer for antiretroviral therapy
and as a component of Stribild; it offers an
effective, well-tolerated, integrase inhibitor-
based single-tablet regimen for HIV treatment.
In terms of PI, co-formulations of COBI/ATV
and COBI/DRV are in development. The low
incidence of neuro-psychiatric side effects with
COBI/EVG compared with EFV, and the lower
prevalence of diarrhoea with COBI/ATV
compared with RTV/ATV, makes it a
potentially attractive alternative to these
commonly prescribed agents. The reduced pill
burden and once-daily administration
118 Infect Dis Ther (2013) 2:111–122
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distinguish COBI/EVG from RTG, the only
other II currently licensed. However, a single-
tablet regimen based on the investigational
integrase, dolutegravir, co-formulated with
abacavir and lamivudine is expected to be
licensed within the next 12 months and is
currently under review by the FDA. Stribild’s
lack of interaction with acid-reducing agents
distinguishes it from ATV and RPV.
There remain several data gaps, and
widespread uptake of Stribild and COBI may
be hampered by these. The male predominance
and high median CD4 cell count of the phase III
trial participants limit data in women and
patients with low CD4 cell counts,
opportunistic infections, malignancy or other
serious co-morbidities, although the WAVES
study, comparing Stribild to Truvada (Gilead
Inc., Foster City, CA, USA) plus RTV/ATV in
women, is currently recruiting.
COBI is associated with drug–drug
interactions, few of which have been studied
to date. Although virological failure with
Stribild was uncommon, patients that did fail
commonly did so with dual-class resistance, and
it remains unclear whether these viral isolates
remain susceptible to dolutegravir. Also, Stribild
is only licensed for use in patients with
creatinine clearance C70 mL/min thus is not
suitable for patients with renal impairment. The
inclusion of TDF in Stribild makes it a less
attractive option for patients with, or at risk of,
osteoporosis, although the renal and bone
concerns are likely to be less if TAF becomes
the preferred tenofovir formulation of COBI-
based single-tablet regimens. Finally, in an
increasingly cost-conscious environment, the
relative benefits of Stribild and COBI will have
to be weighed against any incremental cost
relative to current proprietary medications as
well as forthcoming generic formulations.
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